Clinical Study

Enhancement of Ovarian Malignancy on Clinical Contrast Enhanced MRI Studies

Table 1

Lesion enhancement. Enhancement characteristics of lesion stratified by type of ovarian pathology and reader.

Enhancement characteristics of lesion by ovarian pathology and reader.
Pathology
% lesion enhancement
Reader 1Reader 2
Mean (SD)Median (range)Mean (SD)Median (range)

High grade serous carcinomaPost 1 83.1 (64.9)76.1 (11.3, 272.6)81.0 (64.3)75.6 (−11.4, 275.1)
Highest enhancement136.9 (78.5)126.7 (54.6, 380.7)136.8 (95.7)119.5 (46.8, 490.2)
Other epithelial carcinomaPost 1 136.0 (62.0)148.4 (11.0, 227.7)130.1 (58.9)133.8 (10.2, 246.1)
Highest enhancement163.9 (58.8)177.1 (52.4, 265.0)150.9 (53.1)144.4 (28.9, 246.1)
Other nonepithelial cancerPost 1 76.9 (78.5)74.4 (−13.8, 209.0)66.4 (52.9)57.2 (−2.2, 144.3)
Highest enhancement151.8 (59.1)160.9 (61.6, 242.7)163.6 (44.3)153.4 (122.4, 263.2)
Borderline tumorPost 1 57.2 (34.4)66.0 (8.4, 100.9)58.4 (48.6)62.3 (−0.6, 155.7)
Highest enhancement98.0 (46.4)102.3 (45.8, 191.7)93.4 (47.8)74.8 (42.1, 177.7)

Post 1: enhancement on first postcontrast phase.
Highest: highest enhancement demonstrated on all postcontrast phases.
% lesion enhancement = [(postcontrast lesion SI − precontrast lesion SI)/precontrast lesion SI] × 100.
SI: signal intensity.